anti-Prekallikrein (PK) Antikörper

Kallikreins are a subgroup of serine proteases having diverse physiological functions. Zusätzlich bieten wir Ihnen Prekallikrein Kits (8) und Prekallikrein Proteine (3) und viele weitere Produktgruppen zu diesem Protein an.

Alle Antikörper anzeigen Gen GeneID UniProt
PK 354 P07288
Direkt bei antikoerper-online bestellen
  • +1 877 302 8632
  • +1 888 205 9894 (toll-free)
  • Online bestellen

Top anti-Prekallikrein Antikörper auf

Showing 10 out of 22 products:

Katalog Nr. Reaktivität Wirt Konjugat Applikation Bilder Menge Anbieter Lieferzeit Preis Details
Human Kaninchen Unkonjugiert ICC, IHC, WB DAB staining on IHC-P; Samples: Human Stomach cancer Tissue 100 μg Anmelden zum Anzeigen 13 bis 16 Tage
Human Kaninchen Unkonjugiert IF/ICC, IHC, IP, WB Western blot analysis of the recombinant protein. IHC-P analysis of Human Stomach cancer Tissue, with DAB staining. 100 μg Anmelden zum Anzeigen 11 bis 18 Tage
Human Maus Unkonjugiert ELISA (Capture), ELISA, WB   1 mL Anmelden zum Anzeigen 2 bis 3 Tage
Human Maus Unkonjugiert ELISA, WB   0.2 mg Anmelden zum Anzeigen 3 bis 4 Tage
Human Ziege Unkonjugiert ID, IEP   1 mL Anmelden zum Anzeigen 5 bis 7 Tage
Human Ziege Unkonjugiert ELISA   1 mL Anmelden zum Anzeigen 11 bis 16 Tage
Human Kaninchen PE FACS, ICC, IF, IHC   150 μg Anmelden zum Anzeigen 2 bis 3 Tage
Human Kaninchen FITC FACS, ICC, IF, IHC   150 μg Anmelden zum Anzeigen 2 bis 3 Tage
Human Kaninchen APC FACS, ICC, IF, IHC   150 μg Anmelden zum Anzeigen 2 bis 3 Tage
Human Kaninchen PerCP FACS   150 μg Anmelden zum Anzeigen 2 bis 3 Tage

Weitere Antikörper gegen Prekallikrein Interaktionspartner

Human Prekallikrein (PK) Interaktionspartner

  1. These results shed a light on the genetic background of Benign prostatic hyperplasia and associated lower urinary tract symptoms and its substantial influence on PSA levels.

  2. Studies indicate that ghgh level of gamma-seminoprotein (gama-SM)/Prostate-Specific Antigen (PSA) could be detected in the blood [Review].

  3. Genome-wide association study of prostate-specific antigen levels identifies novel loci independent of prostate cancer.

  4. Men with mild to no lower urinary tract symptoms (LUTS) but increased baseline PSA are at increased risk of developing incident LUTS presumed due to benign prostatic hyperplasia

  5. PSA-density might inform biopsy decisions, and spare some men from the morbidity associated with a prostate biopsy and diagnosis of low-grade prostate cancer.

  6. Differences in fPSA-recovery between all investigated assays were even more pronounced. When applying the tPSA cutoff of 3.1 mug/L recommended for WHO-calibrated assays, the use of higher calibrated assays may lead to unnecessary prostate biopsies. Conversely, if the historical threshold of 4 mug/L is applied when using WHO-calibrated assays, it could lead to falsely omitted prostate biopsies.

  7. PSA was the only independent predictor of extensive lymph node invasion and could be an important preoperative factor for stratifying high-risk patients.

  8. ue to the biocompatibility, multivalency, stability, and high structural homogeneity, the t-PSA-specific landscape phage demonstrates as a novel specific interface in biosensors.

  9. Based on the target-induced catalytic hairpin assembly and bimetallic catalyst, the enzyme-free recycling amplification strategy for sensitive detection of prostate specific antigen (PSA) has been designed

  10. The prepared biosensor can assay from 0 to 500ng/mL of prostate specific antigen (PSA) level within 2h with the detection limit of 1.18ng/mL by the measurement of resistance change. The resistance change was caused by site selective interaction between PSA and PSA-antigen with an inexpensive bench top digital multimeter (5 1/2 digits)

  11. he superwettable f-PSA microchip can accurately detect human serum samples with excellent correlations with chemiluminescence immunoassay in the clinic, demonstrating its great potential as a sensitive and reliable sensing platform for biological analysis and clinical diagnosis.

  12. The 12-week PSA response rate was 88% (22/25) and 22% (4/18), median time to PSA progression was 18.2 months [95% confidence interval (CI), 8.3 months-not reached) and 3.7 months (95% CI, 2.8-5.6 months), and median time on treatment 21 months (range, 2.6-37.5) and 4.9 months (range, 1.3-23.2), for the AAP-naive and post-AAP cohorts, respectively.

  13. The results support that u-PSA provides useful information for predicting predicting biochemical recurrence after radical prostatectomy . This can be beneficial to avoid unnecessary adjuvant treatments or to start them earlier for selected patients

  14. this meta-analysis suggests that PSA -158G/A polymorphism may be a protecting factor against BPH in Caucasian populations, but it may enhance the disease risk in Asians.

  15. Developed risk assessment models for North Chinese patients with 4-50 ng/mL PSA to reduce unnecessary prostate biopsies and increase the detection rate of prostate cancer.

  16. Data show positive associations of relative Gal-3 and relative PSA levels in prostate cancer patients, notably at early clinical time course.

  17. Both the extent of comorbidity and the PSA doubling time should be taken into consideration when deciding on appropriate management and/or clinical trial eligibility at the time of PSA failure.

  18. As restaging in advanced prostate cancer patients is often guided by increases in PSA levels, our results demonstrate that disease progression on enzalutamide can occur without rising PSA levels. Therefore, a disease monitoring strategy that includes imaging not entirely reliant on serial serum PSA measurement may more accurately identify disease progression.

  19. Older men who underwent no PSA testing or incomplete testing were significantly more likely to be diagnosed with high-risk prostate cancer than those who were previously screened. It is reasonable to consider screening in healthy older men likely to benefit from early detection and treatment.

  20. end-of-radiation PSA was significantly associated with survival endpoints in men who received treatment with definitive radiation and ADT. Whether the EOR PSA can be used to modulate treatment intensity merits further investigation.

Prekallikrein (PK) Antigen-Profil

Protein Überblick

Kallikreins are a subgroup of serine proteases having diverse physiological functions. Growing evidence suggests that many kallikreins are implicated in carcinogenesis and some have potential as novel cancer and other disease biomarkers. This gene is one of the fifteen kallikrein subfamily members located in a cluster on chromosome 19. Its protein product is a protease present in seminal plasma. It is thought to function normally in the liquefaction of seminal coagulum, presumably by hydrolysis of the high molecular mass seminal vesicle protein. Serum level of this protein, called PSA in the clinical setting, is useful in the diagnosis and monitoring of prostatic carcinoma. Alternate splicing of this gene generates several transcript variants encoding different isoforms.

Genbezeichner und Symbole assoziert mit anti-Prekallikrein (PK) Antikörper

  • kallikrein related peptidase 3 (KLK3) Antikörper
  • APS Antikörper
  • hK3 Antikörper
  • KLK2A1 Antikörper
  • PSA Antikörper

Bezeichner auf Proteinebene für anti-Prekallikrein (PK) Antikörper

P-30 antigen , gamma-seminoprotein , kallikrein-3 , prostate specific antigen , prostate-specific antigen , semenogelase , seminin

354 Homo sapiens
Ausgewählte Anbieter für anti-Prekallikrein (PK) Antikörper
Haben Sie etwas anderes gesucht?